Filing Details
- Accession Number:
- 0001140361-22-005109
- Form Type:
- 13G Filing
- Publication Date:
- 2022-02-13 19:00:00
- Filed By:
- Shenzhen Sangel Capital Management Ltd Co
- Company:
- Beyondspring Inc. (NASDAQ::BYSI)
- Filing Date:
- 2022-02-14
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Shenzhen Sangel Capital Management Limited Company | 1,066,822 | 187,800 | 1,066,822 | 187,800 | 1,254,622 | 3.22% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
BeyondSpring Inc.
(Name of Issuer)
Ordinary Shares, par value $0.0001 per share
(Title of Class of Securities)
G10830100
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d - 1(b)
☐ Rule 13d - 1(c)
☒ Rule 13d - 1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. G10830100 | 13G | Page 2 of 5 Pages |
| 1 | NAMES OF REPORTING PERSONS | | | ||
| Shenzhen Sangel Capital Management Limited Company | | | |||
| | | ||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | ||||
| (a)☐ | |||||
| (b)☐ | | | |||
| 3 | SEC USE ONLY | | | ||
| | | | |||
| | | ||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | | | ||
| People's Republic of China | | | |||
| | | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER | | | |
| 1,066,822(1) | | | |||
| | | ||||
| 6 | SHARED VOTING POWER | | | ||
| 187,800(2) | | | |||
| | | ||||
| 7 | SOLE DISPOSITIVE POWER | | | ||
| 1,066,822(1) | | | |||
| | | ||||
| 8 | SHARED DISPOSITIVE POWER | | | ||
| 187,800(2) | | | |||
| | | ||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | | | ||
| 1,254,622(1)(2) | | | |||
| | | ||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | | | ||
| ☐ | | | |||
| | | ||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | | | ||
| 3.22% | | | |||
| | | ||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | | | ||
| OO | | | |||
| | | ||||
| (1) | Includes 693,000 ordinary shares of BeyondSpring Inc., par value $0.0001 per share (“Ordinary Shares”), owned directly by Beijing Sangel Fang Sheng Venture Capital (Limited Partnership), 175,000
Ordinary Shares owned directly by Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership), 124,066 Ordinary Shares owned directly by Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership) and 74,756 Ordinary Shares owned
directly by Sangel Star Biomedical Fund LP. Shenzhen Sangel Capital Management Limited Company (the “Reporting Person”) is the sole general partner of each of Beijing Sangel Fang Sheng Venture Capital
(Limited Partnership), Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership), and Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership), and the Reporting Person is an affiliate of Sangel Star Biomedical Fund LP. |
| (2) | Includes 187,800 Ordinary Shares owned directly by Beijing Huarong Sangel Venture Capital (Limited Partnership) (previously named Beijing Sangel Venture Capital (Limited Partnership)) (“Beijing Huarong Sangel”). The Reporting Person and Huarong Tianze Investments Limited (“Huarong
Tianze”) are the general partners of Beijing Huarong Sangel. |
| CUSIP No. G10830100 | 13G | Page 3 of 5 Pages |
SCHEDULE 13G
| Item 1(a). | Name of Issuer: BeyondSpring Inc. (the “Issuer”) |
| Item 1(b). | Address of Issuer’s Principal Executive Offices (as reported by the Issuer): |
| 28 Liberty Street, 39th Floor New York, New York 10005 | |
| Item 2(a). | Name of Person Filing: This Statement on Schedule 13G (this “Statement”) is filed by Shenzhen Sangel Capital Management Limited Company (the “Reporting Person”). |
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
| c/o BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, NY 10005 | |
| Item 2(c). | Citizenship: People’s Republic of China |
| Item 2(d). | Title of Class of Securities: Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”) |
| Item 2(e). | CUSIP Number: G10830100 |
| Item 3. | If this statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b) or (c), check whether the person filing is a: |
| (a) | ☐ | Broker or dealer registered under Section 15 of the Act; | |
| (b) | ☐ | Bank as defined in Section 3(a)(6) of the Act; | |
| (c) | ☐ | Insurance company as defined in Section 3(a)(19) of the Act; | |
| (d) | ☐ | Investment company registered under Section 8 of the Investment Company Act of 1940; | |
| (e) | ☐ | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); | |
| (f) | ☐ | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); | |
| (g) | ☐ | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); | |
| (h) | ☐ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; | |
| (i) | ☐ | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; | |
| (j) | ☐ | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); | |
| (k) | ☐ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). | |
| If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ________________________ | |||
| Item 4. | Ownership: |
| (a) | Amount beneficially owned: 1,254,622* | |
| (b) | Percent of class: 3.22% | |
| (c) | Number of shares as to which such person has: |
| CUSIP No. G10830100 | 13G | Page 4 of 5 Pages |
| (i) | Sole power to vote or to direct the vote: 1,066,822 | |
| (ii) | Shared power to vote or to direct the vote: 187,800 | |
| (iii) | Sole power to dispose or to direct the disposition of: 1,066,822 | |
| (iv) | Shared power to dispose or to direct the disposition of: 187,800 |
| | * The Ordinary Shares reported above include 693,000 Ordinary Shares owned directly by Beijing Sangel Fang Sheng Venture Capital (Limited Partnership) (“Beijing Sangel”), 175,000 Ordinary Shares
owned directly by Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership) (“Shenzhen Sangel Jing”), 124,066 Ordinary Shares owned directly by Shenzhen Sangel Sino-Euro Venture Capital (Limited
Partnership) (“Shenzhen Sangel Sino”), and 74,756 Ordinary Shares owned directly by Sangel Star Biomedical Fund LP (“Sangel Star Biomedical”). The Reporting
Person is the sole general partner of each of Beijing Sangel, Shenzhen Sangel Jing, and Shenzhen Sangel Sino, and the Reporting Person is an affiliate of Sangel Star Biomedical and, as such, has the ability to direct the management of the
business of each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical, including the power to direct decisions regarding the vote and disposition of securities held by each of Beijing Sangel, Shenzhen
Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical; therefore, the Reporting Person may be deemed to have indirect beneficial ownership of the Ordinary Shares held by each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel
Sino, and Sangel Star Biomedical. The Ordinary Shares reported above include 187,800 Ordinary Shares owned directly by Beijing Huarong Sangel
Venture Capital (Limited Partnership) (previously named Beijing Sangel Venture Capital (Limited Partnership)) (“Beijing Huarong Sangel”).
The Reporting Person and Huarong Tianze Investments Limited (“Huarong Tianze”) are the general partners of Beijing Huarong
Sangel and share the ability to direct the management of the business of Beijing Huarong Sangel, including the power to direct decisions regarding the vote and disposition of securities held Beijing Huarong Sangel; therefore, the
Reporting Person and Huarong Tianze may each be deemed to have indirect beneficial ownership of the Ordinary Shares held by Beijing Huarong Sangel. The percentages used in this Schedule 13G/A are calculated based upon the Issuer’s 39,142,253 issued and outstanding Ordinary Shares as of September 30, 2021, as reported by the Issuer in its press release, attached as Exhibit 99.1 to
its Form 6-K filed with the U.S. Securities and Exchange Commission on December 30, 2021. |
| Item 5. | Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the following ☒. |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person: |
| Not Applicable. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable. |
| Item 8. | Identification and Classification of Members of the Group: Not Applicable. |
| Item 9. | Notice of Dissolution of Group: Not Applicable. |
| Item 10. | Certifications: |
| Not Applicable. |
| CUSIP No. G10830100 | 13G | Page 5 of 5 Pages |
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.
Dated: February 14, 2022
| Shenzhen Sangel Capital Management Limited Company | |
| /s/ Mulong Liu | |
| Mulong Liu Legal Representative |